Stocktoria
ALUMIS INC. ALMS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-06-28
ALUMIS INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $24.1M | — | — |
| R&D expense | $386.0M | $265.6M | $137.7M |
| Operating income | -$453.8M | -$300.8M | -$158.2M |
| Income tax | -$8.6M | $0 | $0 |
| Net income | -$243.3M | -$294.2M | -$155.0M |
| EPS (diluted) | $-2.86 | $-10.38 | $-72.08 |
| Operating cash flow | -$369.5M | -$255.1M | -$130.0M |
| Free cash flow | -$370.2M | -$256.8M | -$134.5M |
| Cash & equivalents | $89.7M | $169.5M | $46.0M |
| Total assets | $411.9M | $341.0M | $89.6M |
| Total liabilities | $110.6M | $80.9M | $53.5M |
| Shareholders' equity | $301.3M | $260.1M | -$339.3M |
Source: SEC EDGAR filings · CIK 0001847367 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.